Trials / Completed
CompletedNCT05891262
A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants
A Phase 1, Single-center, Open-label, Single-sequence Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 With Oral Contraceptives in Healthy Female Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the effect of BMS-986196 when coadministered with combined hormonal oral contraceptives (ethinyl estradiol \[EE\] and norethindrone \[NET\]) in healthy female participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986196 | Specified dose on specified days |
| DRUG | Loestrin | Specified dose on specified days |
Timeline
- Start date
- 2023-06-06
- Primary completion
- 2023-08-25
- Completion
- 2023-08-25
- First posted
- 2023-06-06
- Last updated
- 2023-09-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05891262. Inclusion in this directory is not an endorsement.